Ex-Novo executive signs at Radius to capitalize on Amgen's bone-drug setback

With Amgen’s competing bone drug now sidelined, Radius has a big opportunity ahead with its Tymlos launch. And the company is staffing up accordingly. Monday, the Massachusetts biotech said it had brought on Jesper Høiland, former president of Novo Nordisk’s U.S. business, as its new CEO. He’ll replace Bob Ward, who guided the company though its IPO and Tymlos’ journey to approval, which concluded with an FDA nod in late April. Radius’ board "thought long and hard about making sure we have the right leader at the company with the right experience to maximize" the opportunities in front of the company, chairman Kurt Graves said in an interview, and it wanted someone with "true global experience" and multiple launches under his or her belt.